Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Who can take part

• 18-75 years old, male or female
• BMI: 18.0-30.0 kg/m2
• Meet the 2015 ACR/EULAR gout classification criteria
• Fast serum uric acid ≥ 480 μmol/L on 2 different days during the screening perid
• Willing to ues contraceptive measures during the study
• Able and willing to provide a written informed consent

Who cannot take part

• History of acute gout attack within 4 weeks before randomization
• Subjects who have undergone major surgery or organ transplantation within 3 months before randomization
• Subjects with major cardiovascular disease within 6 months before randomization
• Combined use of prohibited drugs
• Participated in other clinical trials within 1 month before randomization
• History of chronic infection or recurrent infection within 1year before randomization
• History of malignant tumor or current history of combined malignant tumor within 5 years before screening
• History of secondary hyperuricemia, refractory gout, or xanthine metabolism disorder
• Subjects with poorly controlled blood pressure or diabetes mellitus
• History of chronic diffuse connective tissue disease and/or massively elevated urate diseases and/or untreated clinically significant thyroid disease
• History of diseases that may affect the in vivo process, safety evaluation, or subjects' participation in the research
• Allergic to ingredient or component of the experimental drug
• History of drug abuse, drug use and/or excessive drinking within 1 year before screening
• The investigators determined that other conditions were inappropriate for participation in this clinical trial
• Abnormal laboratory tests that may affect subjects participating in the research
• Pregnant or nursing women